Brief: Codex Dna Reports Fourth Quarter And Full Year 2021 Financial Results
22/03/2022 20:11
March 22 (Reuters) - Codex DNA Inc DNAY.O :
* CODEX DNA REPORTS FOURTH QUARTER AND FULL YEAR 2021
FINANCIAL
RESULTS AND PROVIDES 2022 GUIDANCE
* Q4 LOSS PER SHARE $0.43
* Q4 REVENUE ROSE 59 PERCENT TO $3.1 MILLION
* SEES 2022 TOTAL REVENUE IN RANGE OF $19 MILLION TO $21
MILLION
Source text for Eikon: ID:nGNX2C3CCR
Further company coverage: DNAY.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Telesis Bio
See all newsBrief: Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Brief: Telesis Bio Plans To Delist Its Securities From The Nasdaq Stock Market
Brief: Telesis Bio Says Co Entered Share Purchase Agreement With Yuan Yang To Sell All Of Outstanding Capital Stock Of Eton Bio
Telesis Bio Inc reports results for the quarter ended in June - Earnings Summary
Telesis Bio Inc expected to post a loss of $4.03 a share - Earnings Preview